A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc

British Journal of Clinical Pharmacology

Volumn 65, Issue SUPPL. 1, 2008, Pages 95-106

  Jacqmin, Philippe ^a   McFadyen, Lynn ^b   Wade, Janet R ^a  

^a Exprimo NV   (Belgium)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

CCR5; HIV; Maraviroc; PD model; Receptor theory; Semimechanistic

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MARAVIROC;

ARTICLE; DRUG BINDING; HUMAN; IC 50; IN VIVO STUDY; INFECTION RATE; MATHEMATICAL MODEL; MOLECULAR MECHANICS; PRIORITY JOURNAL; SIMULATION; TARGET CELL; THEORETICAL MODEL; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; COMPUTER SIMULATION; CYCLOHEXANES; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; RECEPTORS, CCR5; TRIAZOLES; VIRAL LOAD;

EID: 40549090900     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03141.x     Document Type: Article

References (25)

1. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Ricketet G, Smith-Burchnell C, Napier C, Webster R, Armour D, Stammen B, Wood A, Perros M. Maraviroc (UK-427 8 57), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005 49 : 4721 32.
2. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins T, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der Ryst E. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005 11 : 1170 2.
3. McHale M, Abel S, Russell D, Gallagher J, van der Ryst E. Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427 857). In : 3rd IAS Conference on HIV Pathogenesis and Treatment. 2005 July 24-27. Rio de Janeiro, Brazil.
4. Rosario MC, Jacqmin P, Dorr P, van der Ryst E, Hitchcock C. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc. Clin Pharmacol Ther 2005 78 : 508 19.
5. Rosario MC, Poland B, Sullivan J, Westby M, van der Ryst E. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. J Acquir Immune Defic Syndr 2006 42 : 183 91.
6. Rosario MC, Jacqmin P, Dorr P, James I, Jenkins TM, Abel S, van der Ryst E. Population pharmacokinetic- pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients. Br J Clin Pharmacol 2008 65 (Suppl. 1 86 94.
7. De Milito A, Titanji K, Zazzi M. Surrogate markers as a guide to evaluate response to antiretroviral therapy. Curr Med Chem 2003 10 : 349 65.
8. Tsoukas CM, Bernard NF. Markers predicting progression of human immunodeficiency virus-related disease. Clin Microbiol Rev 1994 7 : 14 28.
9. Vergu E, Mallet A, Golmard JL. Available clinical markers of treatment outcome integrated in mathematical models to guide therapy in HIV infection. J Antimicrob Chemother 2004 53 : 140 3.
10. Kenakin T. Pharmacologic Analysis of Drug-Receptor Interaction, 2nd edn. New York : Raven Press, 1993.
11. Rang HP. The receptor concept: pharmacology's big idea. Br J Pharmacol 2006 147 : S9 16.
12. Black JW, Leff P. Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 1983 220 : 141 62.
13. Dorr PK, Dobbs S, Rickett G, Lewis B, Macartney M, Westby M, Perros M. In vitro evaluation of prolonged CCR5 occupancy by small molecule antagonists with anti-HIV activity. Abstr Intersci Conf Antimicrob Agents Chemother 2003 43 : F 1462.
14. Mosley M, Smith-Burchnell C, Mori J, Lewis M, Stockdale M, Huang W, Whitcomb J, Petropoulos CJ, Perros M, Westby M. Resistance to the CCR5 antagonist maraviroc is characterised by dose-response curves that display a reduction in maximal inhibition [abstract 598]. In : 13th Conference on Retroviruses and Opportunistic Infections. 2006 February 5-8; Denver, CO.
15. Pullen S, Sale H, Napier C, Mansfield R, Holbrook M. Maraviroc is a slowly reversible antagonist at the human CCR5 in a CRE luciferase reporter gene assay (abstract 504). In : 13th Conference on Retroviruses and Opportunistic Infections. 2006 February 5-8; Denver, CO.
16. Volterra V. Variazioni e Fluttuazioni del Numero d'Individui in Specie Animali Conviventi. Mem R Accad Naz Dei Lincei 1926 2 : 31 113.
17. Bonhoeffer S. Models of viral kinetics and drug resistance in HIV-1 infection. AIDS Patient Care STDS 1998 12 : 769 74.
18. Bonhoeffer S, May RM, Shaw GM, Nowak MA. Virus dynamics and drug therapy. Proc Natl Acad Sci USA 1997 94 : 6971 6.
19. Funk GA, Fischer M, Joos B, Opravil M, Gunthard HF, Ledergerber B, Bonhoeffer S. Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells. J Acquir Immune Defic Syndr 2001 26 : 397 404.
20. Stephenson RP. A modification of receptor theory. Br J Pharmacol Chemother 1956 11 : 379 93.
21. Clark AJ. The Mode of Action of Drugs on Cells. London : Edward Arnold, 1933.
22. Briz V, Poveda E, Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 2006 57 : 619 27.
23. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 2005 4 : 919 27.
24. Van der Graaf PH, Van Schaick EA, Visser SA, De Greef HJ, Ijzerman AP, Danhof M. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A (1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. J Pharmacol Exp Ther 1999 290 : 702 9.
25. Zuideveld KP, Van der Graaf PH, Newgreen D, Thurlow R, Petty N, Jordan P, Peletier LA, Danhof M. Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats. J Pharmacol Exp Ther 2004 308 : 1012 20.